Second mandate (2011-2013)
Recognising that continued action was required on the part of all stakeholders to implement the HLG-MR policy approach in a context of international cooperation, the NEA established the second mandate of the HLG-MR. The objective of the HLG-MR during its second mandate is to work towards increasing the long-term security of supply of 99Mo and 99mTc , especially through the implementation of the HLG-MR policy approach and its associated recommendations. This will entail actions to maintain transparency on global developments, continue communication with the supply chain and end users, evaluate progress toward implementation and provide additional information and analysis where necessary. The broad deliverables of the HLG-MR second mandate are:
- Sharing information on the status of the 99Mo/99mTc market.
- Communicating the HLG-MR policy approach to governments and other supply chain participants, including working more closely with the health community.
- Providing guidance on specific aspects of implementing the HLG-MR policy approach, such as developing a guidance document on full-cost recovery.
- Supporting the implementation of all aspects of the HLG-MR policy approach, where appropriate and feasible, including working with the health community to study issues that may help them to accept, adjust or become better informed about the policy approach and its consequences for patients.
- Carrying out studies related to security of supply, such as analysing the market and economic impact of converting to using low enriched uranium targets for 99Mo production.
- Evaluating the progress towards the implementation of the HLG-MR policy approach, including through undertaking a periodic review of the supply chain.
- Re-evaluating the policy approach once experience has been obtained.
Last reviewed: 4 December 2013